ACE/ARB Inhibitors - Pipeline Insight, 2024

ACE/ARB Inhibitors - Pipeline Insight, 2024

DelveInsight’s, “ACE/ARB Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in ACE/ARB Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

ACE/ARB Inhibitors Understanding

ACE/ARB Inhibitors: Overview

ACE inhibitors (angiotensin converting enzyme inhibitors) and ARBs (angiotensin-receptor blockers) are used to treat high blood pressure (hypertension) and congestive heart failure, to prevent kidney failure in patients with high blood pressure or diabetes, and to reduce the risk of stroke.

Function –Angiotensin converting enzyme (ACE, EC 3.4.15.1) is a membrane-bound, zinc dependent dipeptidase that catalyzes the conversion of the decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II by removing the two C-terminal amino acids. ACE is well known to be a key part of the rennin-angiotensin system that regulates blood pressure.

ACE/ARB Inhibitors- Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) reduce intraglomerular pressure by inhibiting angiotensin II ̶ mediated efferent arteriolar vasoconstriction. These classes of drugs have a proteinuria-reducing effect independent of their antihypertensive effect.

ACE/ARB Inhibitors Emerging Drugs Chapters

The exact mechanism of ACE inhibitors is not fully known. They do interfere with the renin-angiotensin-aldosterone system, but their effect is not directly related to renin levels in the blood. ACE inhibitors, as the name implies, blocks an angiotensin-converting enzyme that converts angiotensin I to angiotensin II. Decreased production of angiotensin II enhances natriuresis, lowers blood pressure, and prevents remodeling of smooth muscle and cardiac myocytes. Lowered arterial and venous pressure reduces preload and afterload. Also, the hypothesis is that ACE inhibitors interfere with the degradation of bradykinin, which is a peptide that causes vasodilation.

ACE/ARB Inhibitors Emerging Drugs

• Sparsentan: Travere Therapeutics

Sparsentan is a novel small-molecule candidate in Phase 3 development for the treatment of focal segmental glomerulosclerosis (FSGS). FSGS is a pattern of damage to the glomeruli (filter units) of the kidney with numerous causes that often leads to decline in kidney function and progression to end-stage kidney disease (ESKD). The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted sparsentan orphan drug designation for FSGS. Sparsentan is a single molecule designed to selectively block the receptors of two pathways which are associated with kidney disease progression. The receptors are endothelin 1A and angiotensin II type 1.

• Ezetimibe/rosuvastatin + telmisartan : Hanlim Pharm

They are ACE inhibitors, currently in phase 3 of clinical trials for the treatment of Hypercholesterolaemia; Hypertension.

Further product details are provided in the report……..

ACE/ARB Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different ACE/ARB Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on ACE/ARB Inhibitors

There are approx. 3+ key companies which are developing the ACE/ARB Inhibitors. The companies which have their ACE/ARB Inhibitors drug candidates in the most advanced stage, i.e. phase 3 include, Travere Therapeutics.

• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

ACE/ARB Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

ACE/ARB Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses ACE/ARB Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ACE/ARB Inhibitors drugs.

Report Highlights

• In the coming years, the ACE/ARB Inhibitors market is set to change due to the extensive research in this filed, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence ACE/ARB Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• There are several companies involved in developing therapies for ACE/ARB Inhibitors . Launch of emerging therapies of ACE/ARB Inhibitors will significantly impact the market.
• A better understanding of the target mechanism will also contribute to the development of novel therapeutics for ACE/ARB Inhibitors .
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of ACE/ARB Inhibitors ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

ACE/ARB Inhibitors Report Insights

• ACE/ARB Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

ACE/ARB Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing ACE/ARB Inhibitors drugs?
• How many ACE/ARB Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for ACE/ARB Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the ACE/ARB Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for ACE/ARB Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Travere Therapeutics
• Hanlim Pharm
• Alnylam Pharmaceuticals

Key Products

• Sparsentan
• Ezetimibe/rosuvastatin + telmisartan
• ALN AGT